Pharmadrug Inc. (LMLLF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 11:07AM EDT
| Previous close | 0.0252 |
| Open | 0.0242 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0238 - 0.0250 |
| 52-week range | 0.0210 - 0.0575 |
| Volume | |
| Avg. volume | 38,373 |
| Market cap | 2.354M |
| Beta (5Y monthly) | 2.91 |
| PE ratio (TTM) | 1.25 |
| EPS (TTM) | 0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug”), has initiated its regulatory and clinical development plan to evaluate Sairiyo’s patented reformulated enteric coated v
© 2024 Yahoo. All rights reserved.